DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,798 filers reported holding DANAHER CORPORATION in Q2 2021. The put-call ratio across all filers is 1.06 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $620,775 | -3.6% | 2,463 | +1.5% | 0.02% | -33.3% |
| Q4 2022 | $644,174 | +6.7% | 2,427 | +3.9% | 0.03% | +57.9% |
| Q3 2022 | $604,000 | +6.3% | 2,337 | +4.1% | 0.02% | +18.8% |
| Q2 2022 | $568,000 | -78.5% | 2,246 | -74.7% | 0.02% | -69.8% |
| Q1 2022 | $2,644,000 | +164.9% | 8,893 | +192.8% | 0.05% | +165.0% |
| Q4 2021 | $998,000 | +12.5% | 3,037 | +5.0% | 0.02% | +17.6% |
| Q3 2021 | $887,000 | +22.7% | 2,893 | +8.4% | 0.02% | +41.7% |
| Q2 2021 | $723,000 | +40.1% | 2,668 | +15.2% | 0.01% | +33.3% |
| Q1 2021 | $516,000 | +16.5% | 2,315 | +15.3% | 0.01% | -10.0% |
| Q4 2020 | $443,000 | +14.8% | 2,007 | +9.6% | 0.01% | -16.7% |
| Q3 2020 | $386,000 | +28.7% | 1,831 | +5.2% | 0.01% | +9.1% |
| Q2 2020 | $300,000 | -42.7% | 1,740 | -49.3% | 0.01% | -38.9% |
| Q4 2019 | $524,000 | -46.9% | 3,431 | -50.7% | 0.02% | -48.6% |
| Q3 2019 | $986,000 | +3692.3% | 6,966 | +2214.3% | 0.04% | +84.2% |
| Q1 2016 | $26,000 | – | 301 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |